This is the authors' abstract. We don't add key points for this paper.
Psoriatic arthritis (PA) is a chronic autoimmune inflammatory disease characterized by persistent joint inflammation and severe erythemo-squamous plaques on the skin. In recent decades, biological agents such as IL-17 drugs have been applied in the treatment of PA with very good results. The treatment has its adverse effects, but severe pancytopenia is extremely rare. We report a case of а patient who was treated with secukinumab for 3 years and in the background of this treatment unlocked urticaria vasculitis and severe pancytopenia. In relation to psoriatic arthritis, there is almost complete clearing of the skin, but the joint pains are remitting in nature.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Georgiеva et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: